Elicio Therapeutics (ELTX) Assets (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Assets for 7 consecutive years, with $31.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets rose 6.1% year-over-year to $31.3 million; the trailing twelve-month figure through Jun 2026 stood at $31.3 million (up 6.1% YoY), and the FY2025 full-year result was $25.9 million, down 8.22% from the prior year.
• Assets climbed to $31.3 million in Q2 2026 per ELTX's latest filing, from $22.7 million in the prior quarter.
• Across five years, Assets topped out at $81.3 million in Q1 2022 and bottomed at $15.8 million in Q2 2024.
• Historically, Assets has averaged $35.9 million across 5 years, with a median of $28.9 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Assets slumped 76.52% in 2022, then soared 87.48% in 2025.
• Over 5 years, Assets stood at $22.7 million in 2022, then rose by 19.78% to $27.1 million in 2023, then climbed by 3.8% to $28.2 million in 2024, then declined by 8.22% to $25.9 million in 2025, then advanced by 21.14% to $31.3 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $31.3 million, $22.7 million, and $25.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.